Market
Scenario
The
Transthyretin (TTR) amyloidosis market is expected to register a sturdy growth
during the forecast period. Transthyretin (TTR) amyloidosis is a medical
condition characterized by the buildup of abnormal deposits of a protein called
amyloid (amyloidosis) in a body's organs and tissues. It generally affects
peripheral neuropathic or autonomic neuropathy system and cardiac system. The
cardiac form of Transthyretin (TTR) amyloidosis puts patients at the risk of
arrhythmia, cardiomegaly, and orthostatic hypertension. The global ATTR market
is likely to exhibit a robust growth during the forecast period due to the
probability of rising number of ATTR therapeutic drugs launches, increasing
African-American population as they are genetically susceptible to amyloidosis,
increasing healthcare awareness among people, and rising average income of
individuals. However, the growth of this market can be hindered by stringent
regulatory policies, the high cost of ATTR drugs, incorrect diagnosis of ATTR
disorders and limitations of clinical trials. Lack of knowledge about this
condition and unavailability of advanced diagnostic methods in the middle-income
countries are the major challenges to the market.
Top Market Players
- Alnylam Pharmaceuticals
- Pfizer
- Merck
- Ionis Pharmaceuticals Inc.
- Corino Therapeutics Inc
- Arcturus Therapeutics
- Proclara Bioscience
Market
Segmentation
The
global Transthyretin (TTR) amyloidosis market is segmented on the basis of
disease type, treatment, gender, and end-user. Considering the type of disease,
the market is segmented into Transthyretin (TTR) familial amyloid
polyneuropathy, Transthyretin (TTR) familial amyloid cardiomyopathy, and
others. On the basis of treatment, the market is segmented into small molecules
treatment, RNAi therapy, organ transplantation, and others. Small
molecules treatment is further segmented into tafamidis and diflunisal. On
gender basis, it is segmented into male and female. According to end-user, the
market is segmented into hospitals and clinics, ambulatory surgical centers,
and others.
Based on
region the market is segmented into Americas, Europe, Asia Pacific, and the
Middle East and Africa. The American region is segmented into North America and
South America. Similarly, Europe is segmented into Western Europe and Eastern
Europe.
Regional
Market Summary
Americas
dominates the market for Transthyretin (TTR) amyloidosis owing to the
increasing prevalence of amyloidosis among adults and older population and
rising geriatric population which is a major trigger factor for this disease.
For instance, according to a report published by ASCO Journal in 2016 around
4,000 people developed amyloidosis each year in the United States. Thus, this
rising patient pool is going to boost up the market growth during the forecast
period. Additionally, factors such as increasing government initiatives and
funding for research, development in advanced medical treatment options, and
rising use of technologically advanced medical diagnostic devices are likely to
drive the market. The presence of pharmaceutical giants such as Pfizer, Merck,
etc. also propels the market growth in this region.
Europe is
the second largest market and holds a healthy share in the global Transthyretin
(TTR) amyloidosis market. The European market is expected to exhibit robust
growth during the forecast period due to major driving factors such as
availability of advanced treatment facilities, increasing healthcare
expenditure along with growing need for better healthcare infrastructure, and
government initiatives of healthcare reform. It is reported that in the
U.K., around 60 new cases of Transthyretin (TTR) amyloidosis are reported
annually, and the age-specific incidence rate of it is between 5.1 and 12.8 per
million per year. Additionally, established medical device market and
capability of inhabitants to afford diagnostics are aiding the market growth.
However, the inefficacy of treatment and wrong diagnosis are hampering the
market growth of this region.
Asia
Pacific is expected to be the fastest growing market. According to a report
published by the United Nations in 2015the number of older people aged 60 years
or over in the world is predicted to grow by 56% between 2015 and 2030, out of
which 66% of the older population would reside in the Asia Pacific region. This
makes the region prone to Transthyretin (TTR) amyloidosis as chances of its
prevalence increases with the increasing age. Owing to a huge patient pool, a
faster adaptation of healthcare technology, government initiatives to increase
the healthcare quality, and availability favorable insurance and reimbursement
policies, the market growth will be accelerated during the forecast period.
Moreover, key players such as Pfizer, Merck, etc. have been setting up
their regional headquarters and manufacturing plants in countries such as
Singapore, China, Japan, Korea, and Australia. Thus, the growth curve of the
Transthyretin (TTR) amyloidosis market will see a positive trend of growth.
The
Middle East and Africa is expected to show the least growth in the market due
to some major factors such as lack of awareness and limited access and
availability of treatment facilities. In the Middle East, the United Arab
Emirates and Saudi Arabia are the largest markets owing to the development of
the healthcare industry and rising availability of specialty care centers. But
the market might show a steady growth due to the genetical susceptibility of
Africans for transthyretin amyloidosis and government initiatives to improve
the quality of healthcare in this region.
Detailed Table
of Contents:
Chapter 1. Report Prologue
Chapter 2. Market
Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research
Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
...Continued
About US:
Market
Research Future (MRFR), enable customers to unravel the complexity of various
industries through Cooked Research Report (CRR), Half-Cooked Research Reports
(HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research
& Consulting Services.
Contact Us:
Market
Research Future
Office
No. 528, Amanora Chambers
Magarpatta
Road, Hadapsar,
Pune
- 411028
Maharashtra,
India
Phone:
+1 646 845 9312
Email:
sales@marketresearchfuture.com
No comments:
Post a Comment